Author(s): WANG Wei, CUI Li-hong, Medical School of Chinese PLA, Navy General Hospital
Pages: 1036-1039
Year: 2016 Issue:  9
Journal: Chinese Journal of New Drugs
Keyword:  rifaximin; Bifid-triple viable capsule; middle-aged and elderly patients; acute infectious diarrhea;
Abstract: Objective: To evaluate the efficacy of rifaximin tablet combined with Bifid-triple viable capsule in middle-aged and elderly patients of acute infectious diarrhea. Methods: Totally 84 middle-aged and elderly patients of acute infectious diarrhea treated in our hospital from May 2014 to December 2015 were selected. The subjects were randomly and equally divided into two groups. They took rifaximin tablet combined with Bifid-triple viable capsule or Bifid-triple viable capsule alone( control). The curative effects,symptom scores,average time of checking diarrhea and adverse event rates of two groups were compared. Results: The total effective rate was higher in combination group( 92. 86%,39 /42) than in control group( 76. 19%,32 /42; P < 0. 05). After treatment,the symptom scores were significantly lower in combination group( 1. 42 ± 0. 82) than in control group( 2. 36 ±1. 93,P < 0. 05). Average time of checking diarrhea was significantly shorter in combination group( 40. 66 ±11. 45 h) than in control group( 48. 23 ± 12. 28,P < 0. 05). The adverse event rates had no significant difference between combination group( 4. 76%,2 /42) and control group( 7. 14%,3 /42; P > 0. 05). Conclusion: The combination of rifaximin tablets with Bifid-triple viable capsule has a better efficacy in the middle-aged and elderlypatients of acute infectious diarrhea,shortening the time of checking diarrhea and relieving the patient’s pain. The adverse event rate is low,so the therapy is safe.